Annual Secretarial Compliance Report under Reg. 24(A) of SEBI (LODR) Regulations, 2015 for the year ended on 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dipna Pharmachem Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26, which reveals multiple regulatory non-compliances. The company failed to appoint a qualified Company Secretary as Compliance Officer (Regulation 6(1)) for multiple quarters, resulting in recurring fines. It also delayed submission of Quarterly Financial Results (Regulation 33) and Investor Complaints statement (Regulation 13(3)). BSE has levied total fines of approximately Rs. 7.07 lakh for these violations. The management has stated they are in the process of appointing a qualified Company Secretary. The company otherwise maintains compliance with Secretarial Standards, related party transactions, insider trading norms, and website disclosures.
This filing highlights weak corporate governance at Dipna Pharmachem, with repeated non-compliance issues attracting fines exceeding Rs. 7 lakh. The persistent failure to appoint a Compliance Officer raises concerns about regulatory oversight and could negatively impact investor confidence. Shareholders should monitor whether the company rectifies these compliance gaps promptly.